Evidence map›Paper›PMID 38473273›Full record

ReviewCancers2024

Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment.

Shirin Bonni, David N Brindley, M Dean Chamberlain, Nima Daneshvar-Baghbadorani, Andrew Freywald, Denise G Hemmings, Sabine Hombach-Klonisch, Thomas Klonisch, Afshin Raouf, Carrie Simone Shemanko and 5 more

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Shirin BonniDepartment of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB T2N 4N1, Canada.
David N BrindleyDepartment of Biochemistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.ORCID 0000-0003-2227-0020
M Dean ChamberlainDivision of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 0W8, Canada.ORCID 0000-0003-1813-8545
Nima Daneshvar-BaghbadoraniDivision of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 0W8, Canada.
Andrew FreywaldDepartment of Pathology, Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Denise G HemmingsCancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Sabine Hombach-KlonischDepartment of Human Anatomy and Cell Science, Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.ORCID 0000-0001-8071-2486
Thomas KlonischDepartment of Human Anatomy and Cell Science, Faculty of Health Sciences, College of Medicine, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.ORCID 0000-0003-0448-6741
Afshin RaoufDepartment of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB R3E OT5, Canada.ORCID 0000-0002-9188-7537
Carrie Simone ShemankoThe Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB T2N 4N1, Canada.ORCID 0000-0002-5260-6210
Diana TopolnitskaDepartment of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB R3E OT5, Canada.
Kaitlyn VisserCancer Research Institute of Northern Alberta, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Franco J VizeacoumarDivision of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 0W8, Canada.ORCID 0000-0002-6452-5207
Edwin WangDepartment of Biochemistry and Molecular Biology, Medical Genetics, and Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada.
Spencer B GibsonDepartment of Oncology, University of Alberta, Edmonton, AB T6G 2R3, Canada.ORCID 0000-0003-0119-732X
University of Alberta · CAUniversity of Saskatchewan · CAUniversity of Calgary · CACancerCare Manitoba · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastasis remains a major challenge in treating breast cancer. Breast tumors metastasize to organ-specific locations such as the brain, lungs, and bone, but why some organs are favored over others remains unclear. Breast tumors also show heterogeneity, plasticity, and distinct microenvironments. This contributes to treatment failure and relapse. The interaction of breast cancer cells with their metastatic microenvironment has led to the concept that primary breast cancer cells act as seeds, whereas the metastatic tissue microenvironment (TME) is the soil. Improving our understanding of this interaction could lead to better treatment strategies for metastatic breast cancer. Targeted treatments for different subtypes of breast cancers have improved overall patient survival, even with metastasis. However, these targeted treatments are based upon the biology of the primary tumor and often these patients' relapse, after therapy, with metastatic tumors. The advent of immunotherapy allowed the immune system to target metastatic tumors. Unfortunately, immunotherapy has not been as effective in metastatic breast cancer relative to other cancers with metastases, such as melanoma. This review will describe the heterogeneic nature of breast cancer cells and their microenvironments. The distinct properties of metastatic breast cancer cells and their microenvironments that allow interactions, especially in bone and brain metastasis, will also be described. Finally, we will review immunotherapy approaches to treat metastatic breast tumors and discuss future therapeutic approaches to improve treatments for metastatic breast cancer.

Indexed as

bone and brain metastasisbreast cancerclonal heterogeneityimmunotherapymetastasis

Identifiers

PMID38473273
PMCPMC10931297
OpenAlexW4392111425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.